Table 2.
Screening tests for transplant candidates
| Tests | Comments/Action Required for Abnormal Results |
|---|---|
| HIV-1 and 2 | HIV-related management as indicated |
| HTLV-1 and 2 | Counselling as indicated |
| Hepatitis A | IgG and IgM serology |
| Hepatitis B | Obtain full panel of hepatitis B serology, including surface antigen and anti-core antibody |
| Hepatitis C | |
| Hepatitis D | Obtain if hepatitis B seropositive |
| CMV | Obtain IgG; urine culture for seropositive infants <2 years |
| EBV | Viral capsid antigen and EBNA |
| Herpes simplex virus | |
| Varicella zoster virus | Vaccinate seronegative candidates at least 6 weeks before transplantation |
| Toxoplasma gondii | Obtain heart, heart-lung candidates |
| Measles | Immunize if ≥3 months before expected transplantation |
| Mumps | Immunize if ≥3 months before expected transplantation |
| Rubella | Immunize if ≥3 months before expected transplantation |
| Mycobacterium tuberculosis | Mantoux test; IGRA being evaluated; intervention for latent TB may be required |
| Strongyloides sterocoralis | Positive serology requires intervention; ivermectin |
| Respiratory tract pathogens | Sputum cultures on patients with cystic fibrosis and other heart-lung transplant candidates; Aspergillus colonization indication for suppressive therapy |
| Radiographic imaging | These tests are as clinically indicated |
Abbreviations: EBNA, Epstein-Barr nuclear antigen; HTLV, human T-lymphotrophic virus; IGRA, interferon-gamma release assays.